Vanguard Portfolio Management’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
Other funds holding CDLX
CIP
6CM
KGAMU
WPM
RC
QOP
Vanguard Portfolio Management's CDLX Position: Q2 2026 in Review
Vanguard Portfolio Management sold out of Cardlytics (CDLX) in Q2 2026, closing a stake of 17,220 shares — an estimated $181K sold.
Vanguard Portfolio Management first reported a position in CDLX in Q1 2026 and held it in 1 quarter. The position peaked at $181K in Q1 2026. 41 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.
- Vanguard Portfolio Management reported no remaining Cardlytics position as of Q2 2026 after selling out during the quarter.
- Vanguard Portfolio Management sold 17,220 Cardlytics shares in Q2 2026, an estimated $181K.
- Vanguard Portfolio Management first reported a position in Cardlytics in Q1 2026 and held it in 1 quarter.
- Vanguard Portfolio Management's Cardlytics position peaked at $181K in Q1 2026.
- 41 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.
Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.